Health Score

0 Excellent

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 10 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact10 DOIs

DOIs for this ISSN

Showing the top 5 of 123 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Translocation Tales: Unraveling the MYC Deregulation in Burk… (10.3390/lymphatics1020010)	ORCID	19.45	5
2	Live to Move and Move to Live: The Health of the Lymphatic S… (10.3390/lymphatics2020004)	ORCID	17.47	4
3	Understanding the Role of Bispecific Antibodies in the Manag… (10.3390/lymphatics1030015)	ORCID	11.93	2
4	Cancer Metastasis Through the Lymphatics: Invasion and Disse… (10.3390/lymphatics3030017)	ORCID	7.53	1
5	Publisher’s Note: Lymphatics, a New Open Access Journal (10.3390/lymphatics1010001)		0.00	0
6	The Role of Sentinel Node Mapping and Lymphadenectomies in V… (10.3390/lymphatics1010002)		0.00	20
7	Predictor Factors for the Detection of Positive Nodes in Pat… (10.3390/lymphatics1010003)		0.00	0
8	Lymphoscintigraphy versus Indocyanine Green Lymphography—Whi… (10.3390/lymphatics1010004)		0.00	15
9	What Is Next in Pediatric B-Cell Precursor Acute Lymphoblast… (10.3390/lymphatics1010005)		0.00	4
10	FDG PET/CT as a Tool for Early Detection of Bleomycin-Induce… (10.3390/lymphatics1010006)		0.00	0
11	Diagnosis and Molecular Pathology of Lymphoblastic Leukemias… (10.3390/lymphatics1020007)		0.00	9
12	Trends in Lymphadenectomy for Esophageal/Esophagogastric Jun… (10.3390/lymphatics1020008)		0.00	1
13	Lymphatics: Future Perspectives Unrealized Potential (10.3390/lymphatics1020009)		0.00	3
14	Diagnosis and Molecular Pathology of Lymphoblastic Leukemias… (10.3390/lymphatics1020011)		0.00	9
15	Diagnosis and Molecular Pathology of Lymphoblastic Leukemias… (10.3390/lymphatics1020012)		0.00	6
16	The Lymphatic System—A Surgeon’s Point of View (10.3390/lymphatics1020013)		0.00	0
17	Scanning Electron Microscopy Analysis of Lymphatic Regenerat… (10.3390/lymphatics1030014)		0.00	1
18	It Is Time to Curb the Dogma in Lymphedema Management (10.3390/lymphatics1030016)	ORCID	0.00	0
19	Evolution of Radiation Fields from Involved Field to Involve… (10.3390/lymphatics1030017)		0.00	5
20	Incorporating Immunotherapy with Radiotherapy for Lymphomas (10.3390/lymphatics1030018)		0.00	1
21	Motion Management: The Road Map to Accurate Radiation Treatm… (10.3390/lymphatics2010001)		0.00	0
22	A Review of Anti-CD20 Antibodies in the Management of B-Cell… (10.3390/lymphatics2010002)		0.00	11
23	Paraneoplastic Syndromes in Hodgkin’s Lymphoma (10.3390/lymphatics2010003)		0.00	3
24	BCL2 Protein Progressively Declines during Robust CLL Clonal… (10.3390/lymphatics2020005)		0.00	2
25	The Rise of Lymphatic Intervention: A Rapid Evolution (10.3390/lymphatics2020006)		0.00	1
26	The Postmortem Evaluation of Anatomical Thymic Parameters in… (10.3390/lymphatics2020007)		0.00	0
27	Evaluation of Sentinel Lymph Nodes in Complex Atypical Endom… (10.3390/lymphatics2020008)		0.00	2
28	Compression Wraps—Providing Solutions for Complex Lymphatic… (10.3390/lymphatics2020009)		0.00	0
29	Climate and Climatic Variations’ Impact on Lymphoedema: Pati… (10.3390/lymphatics2020010)		0.00	1
30	Prevalence and Quality of Life in Patients with Lymphoedema… (10.3390/lymphatics2030011)		0.00	1
31	Persistent B-Cell Stimulation or B-Cell Repertoire Anomalies… (10.3390/lymphatics2030012)		0.00	0
32	MicroRNA: A Signature for the Clinical Progression of Chroni… (10.3390/lymphatics2030013)		0.00	0
33	T-Cells Rich Classical Hodgkin Lymphoma, a Pathology Diagnos… (10.3390/lymphatics2030014)		0.00	1
34	Characterization of Photo-Crosslinked Methacrylated Type I C… (10.3390/lymphatics2030015)		0.00	3
35	Lymphovascular Tumoral Emboli in Inflammatory Breast Cancer… (10.3390/lymphatics2040016)		0.00	4
36	The Current State of Lymphedema Surgery (10.3390/lymphatics2040017)		0.00	3
37	Endovascular and Percutaneous Lymphatic Interventions in Can… (10.3390/lymphatics2040018)		0.00	2
38	Management of Secondary Immunodeficiency Following T-Cell-En… (10.3390/lymphatics2040019)		0.00	2
39	Ultrastaging and Low-Volume Metastatic Disease in Early-Stag… (10.3390/lymphatics2040020)		0.00	0
40	Soluble IL-2R as a Marker of T Cell Activation in Immune-Med… (10.3390/lymphatics3010001)		0.00	3
41	Advancements in Multiple Myeloma Therapies: A Comprehensive… (10.3390/lymphatics3010002)		0.00	1
42	Associations Between Immune-Related Conditions and Lymphoid… (10.3390/lymphatics3010003)		0.00	1
43	Exploring Lymphangioma: A Synthesis of the Literature and Cl… (10.3390/lymphatics3010004)		0.00	1
44	Outcomes and Prognostic Assessment of Post-Transplant Lympho… (10.3390/lymphatics3010005)		0.00	1
45	Effect of ABCB1 Expression on Measurable Residual Disease in… (10.3390/lymphatics3010006)		0.00	1
46	Gata3 Insufficiency Accelerates Recanalization of Damaged Ly… (10.3390/lymphatics3010007)		0.00	0
47	Advances and Techniques in Medical Imaging and Minimally Inv… (10.3390/lymphatics3010008)		0.00	2
48	New Facets of Hematolymphoid Eponymic Diseases (10.3390/lymphatics3020009)		0.00	0
49	Immunoglobulin-Related Fibroinflammatory Diseases of Uncerta… (10.3390/lymphatics3020010)		0.00	0
50	Lipoperoxides as Prognostic Markers in Pediatric B-Acute Lym… (10.3390/lymphatics3020011)		0.00	1